Optimi Health (OPTH) Highlights Australia Psychedelic Therapy Expansion Following TGA Framework Update

LOS ANGELES, CA - May 29, 2026 (NEWMEDIAWIRE) - Optimi Health (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN), a commercial-stage psychedelic pharmaceutical manufacturer, welcomed final recommendations from Australia's Therapeutic Goods Administration regarding its Authorized Prescriber scheme for psilocybin and MDMA. The updated framework broadens eligible therapy teams, expands treatment settings beyond hospital environments and supports scaling of psychedelic-assisted therapy across Australia, where authorized psychiatrists can prescribe Optimi's GMP-compliant MDMA for PTSD and psilocybin for treatment-resistant depression.

The company said the revised framework could accelerate adoption of psychedelic-assisted therapy by increasing workforce capacity, particularly in rural and regional areas, while expanding reimbursement opportunities across both public and private payers. Optimi also noted that no serious adverse events have been reported under Australia's regulated commercial psychedelic treatment program since December 2025, supporting continued expansion of what the company describes as the world's most advanced commercial market for prescribed psilocybin and MDMA therapies.

To view the full press release, visit https://nnw.fm/yYW7j

About Optimi Health Corp.

Optimi Health Corp. is a Canadian GMP-certified pharmaceutical manufacturer specializing in the regulated production and international export of MDMA and psilocybin for prescription-based mental health therapies.

For more information, please visit https://www.optimi.net/

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Forward Looking Statements

Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law.

View the original release on www.newmediawire.com